Inventor · disambiguated record
Markus Von Raumer
Also filed as: VON RAUMER MARKUS
19 granted patents·11 pending applications·51 citations·filing 2004–2025
92Inventor score
Files withIDORSIA PHARMACEUTICALS LTD16GRUENENTHAL GMBH6GRUSS MICHAEL2VIATRIS ASIA PACIFIC PTE LTD2ABELE STEFAN1
Top patents by PatentIndex Score
30 records- 0196US11680058B2Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentanIDORSIA PHARMACEUTICALS LTD·Filed 2021·Granted Jun 20, 2023·5 cites·21 claims
- 0289US10919881B2Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentanIDORSIA PHARMACEUTICALS LTD·Filed 2018·Granted Feb 16, 2021·10 cites·24 claims
- 0386US11059803B2Crystalline form of N-[1-(5-cyano-pyridin-2- ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamideIDORSIA PHARMACEUTICALS LTD·Filed 2018·Granted Jul 13, 2021·2 cites·12 claims
- 0484US12297189B2Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentanIDORSIA PHARMACEUTICALS LTD·Filed 2023·Granted May 13, 2025·0 cites·25 claims
- 0583US11365209B2Crystalline formsIDORSIA PHARMACEUTICALS LTD·Filed 2020·Granted Jun 21, 2022·1 cites·46 claims
- 0683US10023560B2Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonistIDORSIA PHARMACEUTICALS LTD·Filed 2017·Granted Jul 17, 2018·3 cites·13 claims
- 0782US9062014B2Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-oneBONHAM NICHOLAS·Filed 2009·Granted Jun 23, 2015·18 cites·20 claims
- 0881US9790208B2Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonistIDORSIA PHARMACEUTICALS LTD·Filed 2014·Granted Oct 17, 2017·4 cites·6 claims
- 0980US10730896B2Crystalline formsIDORSIA PHARMACEUTICALS LTD·Filed 2017·Granted Aug 4, 2020·1 cites·16 claims
- 1078US9914720B2Crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[D]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonistsIDORSIA PHARMACEUTICALS LTD·Filed 2014·Granted Mar 13, 2018·3 cites·12 claims
- 1173US7884247B2Salt of dimethylaminomethyl-phenyl-cyclohexane and crystalline forms thereofGRUENENTHAL GMBH·Filed 2006·Granted Feb 8, 2011·1 cites·18 claims
- 1270US8492555B2Salts of isobutyric acid (1 R*, 2R*, 4R*)-2-(2-{[3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-methyl-amino}-ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl esterABELE STEFAN·Filed 2009·Granted Jul 23, 2013·2 cites·13 claims
- 1370US2010076085A1HCl Polymorphs of 3-((2-(Dimethylamino)methyl-(cyclohex-1-yl))phenolGRUENENTHAL GMBH·Filed 2009·Application pending·0 cites
- 1469US11555025B2Crystalline form of N-[1-(5-cyano-pyridin-2-ylmethyl)-1 H-pyrazol-3-yl]-2- [4-(1-trifluoromethyl-cyclopropyl)-phenyl-acetamideIDORSIA PHARMACEUTICALS LTD·Filed 2021·Granted Jan 17, 2023·0 cites·2 claims
- 1567US12227532B2Crystalline formsVIATRIS ASIA PACIFIC PTE LTD·Filed 2022·Granted Feb 18, 2025·0 cites·14 claims
- 1666US2025163086A1Crystalline FormsVIATRIS ASIA PACIFIC PTE LTD·Filed 2025·Application pending·0 cites
- 1764US8058476B2HCI polymorphs of 3-((2-(dimethylamino)methyl(cyclohex-1-yl)) phenolGRUSS MICHAEL·Filed 2008·Granted Nov 15, 2011·0 cites·10 claims
- 1857US2024116913A1A crystalline form of (4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(r)-3-(3-[1,2,3]triazol-2-yl-benzyl)-morpholin-4-yl]-methanoneIDORSIA PHARMACEUTICALS LTD·Filed 2022·Application pending·0 cites
- 1957US2013245125A1HCl Polymorphs of 3-((2-(Dimethylamino)methyl(cyclohex-1-yl))phenolGRUENENTHAL GMBH·Filed 2013·Application pending·0 cites
- 2055US2025340520A1Crystalline forms of sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amideIDORSIA PHARMACEUTICALS LTD·Filed 2023·Application pending·0 cites
- 2153US11339148B2Crystalline forms of the CXCR7 receptor antagonist (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amideIDORSIA PHARMACEUTICALS LTD·Filed 2019·Granted May 24, 2022·0 cites·32 claims
- 2253US7892354B2Process for the parallel detection of crystalline forms of molecular solidsSOLVIAS AG·Filed 2004·Granted Feb 22, 2011·1 cites·10 claims
- 2353US2023255987A1Aqueous pharmaceutical composition comprising a p2y12 receptor antagonistIDORSIA PHARMACEUTICALS LTD·Filed 2021·Application pending·0 cites
- 2451US2012178809A1Salt of Dimethylaminomethyl-Phenyl-Cyclohexane and Crystalline Forms ThereofGRUSS MICHAEL·Filed 2012·Application pending·0 cites
- 2550US10351560B2Crystalline formsIDORSIA PHARMACEUTICALS LTD·Filed 2016·Granted Jul 16, 2019·0 cites·13 claims
- 2650US7683179B2Lercanidipine saltsRECORDATI IRELAND LTD·Filed 2005·Granted Mar 23, 2010·0 cites·34 claims
- 2750US2011251287A1Hci polymorphs of 3-((2-(dimethylamino)methyl (cyclohex-1-yl))phenolGRUENENTHAL GMBH·Filed 2011·Application pending·0 cites
- 2848US2011046230A1Salt of Dimethylaminomethyl-Phenyl-Cyclohexane and Crystalline Forms ThereofGRUENENTHAL GMBH·Filed 2010·Application pending·0 cites
- 2945US2022265658A1Pharmaceutical composition comprising a tetrahydropyrazolopyrimidinone compoundIDORSIA PHARMACEUTICALS LTD·Filed 2020·Application pending·0 cites
- 3042US2007032551A1Salt of dimethylaminomethyl-phenyl-cyclohexane and crystalline forms thereofGRUENENTHAL GMBH·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Markus Von Raumer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →